Quadrivalent Human Papillomavirus Vaccine Now for Males, Too

New recommendations — for males — include routine use of HPV4 at ages 11 or 12 years and vaccination through age 26 for those who have not completed the three-dose series.

Background: Human papillomavirus (HPV) infection is the most common sexually transmitted disease in the U.S. HPV serotypes 16 and 18 are responsible for about 70% of cervical cancers; serotypes 6 and 11 underlie about 90% of genital warts. Quadrivalent HPV vaccine (HPV4), which contains these four serotypes, received FDA approval in June 2006 for use in females. Bivalent HPV vaccine (HBV2; serotypes 16 and 18) was licensed in October 2009, also for use in females.

In October 2009, on the basis of additional studies, the FDA licensed HPV4 for use in males aged 9 through 26 years to prevent genital warts. At that time, the Advisory Committee on Immunization Practices (ACIP) stated that the vaccine may be given to males in this age group. Now,…

Author

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

Quadrivalent Human Papillomavirus Vaccine Now for Males, Too

Topics

Author